MediPharm Labs

(TSX) LABS

Current PriceCA$0.08

Market CapCA$33.99M

Since IPO (2018)-96%

5 Year-82%

1 Year+14%

1 Month+14%

MediPharm Labs last closing stock price
Metric	Price	Date
Last close	CAD 0.08	2026-07-17

MediPharm Labs stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+6.67%	CAD 0.08	2026-07-10
1 month	+14.29%	CAD 0.07	2026-06-17
3 month	+23.08%	CAD 0.07	2026-04-17
Year to date	+23.08%	CAD 0.07	2025-12-31
1 year	+14.29%	CAD 0.07	2025-07-17
3 year	+33.33%	CAD 0.06	2023-07-18
5 year	-81.82%	CAD 0.44	2021-07-16
Since inception	-96.48%	CAD 2.20	2018-10-05

MediPharm Labs Financials at a Glance

Market Cap

CA$33.99M

Revenue (TTM)

CA$43.28M

Net Income (TTM)

-CA$8.75M

EPS (TTM)

-CA$0.02

P/E Ratio

-3.85

Dividend

CA$0.00

Beta (Volatility)

0.86 (Low)

Dividend

CA$0.00

Beta (Volatility)

0.86 (Low)

Price

CA$0.08

Volume

803,146

Open

CA$0.09

Price

CA$0.08

Volume

803,146

Open

CA$0.09

Previous Close

CA$0.08

Daily Range

CA$0.08 - CA$0.09

52-Week Range

CA$0.06 - CA$0.10

Estimated Earnings Date

Aug 13, 2026

Dividend

CA$0.00

Beta (Volatility)

0.86 (Low)

Price

CA$0.08

Volume

803,146

Open

CA$0.09

Previous Close

CA$0.08

Daily Range

CA$0.08 - CA$0.09

52-Week Range

CA$0.06 - CA$0.10

Estimated Earnings Date

Aug 13, 2026

LABS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MediPharm Labs

MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations.

Products and Services

Pharmaceutical-grade cannabis oils and concentrates
Advanced cannabinoid-based formulations
GMP-certified flower procurement and logistics services

Growth Outlook

Revenue of CAD 8.96 million in Q1 2026, showing potential for recovery
Gross profit margin improved to 38.7% in Q1 2026
Strong market presence in Canada, Australia, and Germany

Financial Highlights

Trailing twelve months (TTM) revenue of CAD 43.5 million
Current ratio of 3.02 indicates strong liquidity
Net income of CAD -867,000 in Q1 2026, reflecting ongoing operational challenges

MediPharm Labs Corp. has established itself as a key player in the pharmaceutical cannabis sector, focusing on high-quality products and comprehensive services. The recent quarterly revenue indicates a potential upward trend, while the gross profit margin reflects improved operational efficiency. The company's strong liquidity position, as evidenced by a current ratio of 3.02, suggests it is well-equipped to navigate financial challenges. Despite reporting a net loss in the latest quarter, the overall market presence and product offerings position MediPharm Labs for future growth in the expanding cannabis industry.

AI Generated • Jul 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

127

CEO

Greg Hunter, MBA, CPA

Website

www.medipharmlabs.com

Headquarters

Barrie, ON L4N 2L1, CA

LABS Financials

Key Financial Metrics (TTM)

Gross Margin

30.63%

Operating Margin

-20.37%

Net Income Margin

-20.21%

Return on Equity

-23.55%

Return on Capital

-23.35%

Return on Assets

-20.05%

Earnings Yield

-25.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$33.99M

Shares Outstanding

424.86M

Volume

803.15K

Avg. Volume

314.54K

Financials (TTM)

Gross Profit

CA$13.26M

Operating Income

-CA$8.82M

EBITDA

-CA$7.06M

Operating Cash Flow

-CA$3.27M

Capital Expenditure

-CA$59.00K

Free Cash Flow

-CA$3.33M

Cash & ST Invst.

CA$9.87M

Total Debt

CA$18.00K

MediPharm Labs Performance Analysis

MediPharm Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CAD 22,117,000	1.9%
2023	2023-12-31	CAD 33,062,000	49.5%
2024	2024-12-31	CAD 41,961,000	26.9%
2025	2025-12-31	CAD 45,124,000	7.5%

MediPharm Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	9.3%
Q3	2025-09-30	-3.0%
Q4	2025-12-31	-3.4%
Q1	2026-03-31	-19.0%

MediPharm Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CAD -0.11	-50.6%
2023	2023-12-31	CAD -0.04	-66.8%
2024	2024-12-31	CAD -0.03	-27.2%
2025	2025-12-31	CAD -0.02	-24.4%

MediPharm Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-911.1%
Q3	2025-09-30	44.0%
Q4	2025-12-31	11.8%
Q1	2026-03-31	55.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

CA$8.96M

-17.1%

Gross Profit

CA$3.47M

-17.0%

Gross Margin

38.71%

N/A

Market Cap

CA$33.99M

N/A

Market Cap/Employee

CA$267.63K

N/A

Employees

127

N/A

Net Income

-CA$867.00K

-124.0%

EBITDA

-CA$466.00K

-963.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

CA$9.87M

+16.9%

Total Debt

CA$18.00K

-85.6%

Accounts Receivable

CA$6.53M

-16.2%

Inventory

CA$8.47M

-20.0%

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$18.00K

-80.9%

Return on Assets

-20.05%

N/A

Return on Invested Capital

-25.12%

N/A

Free Cash Flow

-CA$779.00K

+74.5%

Operating Cash Flow

-CA$778.00K

+74.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RVX.TOResverlogix Corp.

RVX.TOResverlogix Corp.CA$0.10+0.00%

ROMJ.VRubicon Organics Inc.

ROMJ.VRubicon Organics Inc.CA$0.45+0.00%

ADK.VDIAGNOS Inc.

ADK.VDIAGNOS Inc.CA$0.23-2.17%

CWEB.TOCharlotte's Web Holdings, Inc.

CWEB.TOCharlotte's Web Holdings, Inc.CA$0.32-3.03%

AVCN.TOAvicanna Inc.

AVCN.TOAvicanna Inc.CA$0.13-3.85%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

NOKNokia

NOKNokia$10.12-0.03%

PATHUiPath

PATHUiPath$12.15+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$123.99-0.05%

TAT&T

TAT&T$21.81-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.53-0.05%

Questions About LABS

What is the current price of MediPharm Labs?

MediPharm Labs is trading at CA$0.08 per share.

What is the 52-week range for MediPharm Labs?

Over the past 52 weeks, MediPharm Labs has traded between CA$0.06 and CA$0.10.

How much debt does MediPharm Labs have?

As of the most recent reporting period, MediPharm Labs reported total debt of CA$18.00K.

How much cash does MediPharm Labs have on hand?

MediPharm Labs reported CA$9.87M in cash and cash equivalents in its most recent financial results.

What is MediPharm Labs’s dividend yield?

MediPharm Labs does not currently have a dividend yield.

MediPharm Labs

MediPharm Labs Financials at a Glance

LABS News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MediPharm Labs

LABS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MediPharm Labs Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LABS

What is the current price of MediPharm Labs?

What is the 52-week range for MediPharm Labs?

How much debt does MediPharm Labs have?

How much cash does MediPharm Labs have on hand?

What is MediPharm Labs’s dividend yield?

Premium Investing Services